Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xaluritamig in High-risk Biochemical Recurrence of Nonmetastatic Castration-sensitive Prostate Cancer
NCT06555796Phase 1Active, not recruiting
- Sponsor
- Amgen
- Start
- Sep 2024
- Primary completion
- Mar 2027
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of xaluritamig in prostate cancer (PCa), sponsored by Amgen. Primary endpoints: Treatment-emergent Adverse Events at 2 years and Treatment-related Adverse Events at 2 years. Started Sep 2024; status: active, not recruiting.
02
Drugs
xaluritamig
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06555796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06555796.